Pyc Therapeutics Ltd has released a press release.
PYC to Start Human Trials in Second Blinding Eye Disease
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Story so far
Earlier from PYC Therapeutics
- Visual Improvement in Multiple RP11 Patients
- RP11 Clinical Trial Update - Amended
- RP11 Clinical Trial Update
- Extension of RP11 Single Dose Study Into Multiple Dose Study
- Initial Dosing Completed in Cohort 1 of RP11 MAD Study
Later from PYC Therapeutics
- Appendix 4E and Audited Financial Statements
- FDA Grants Rare Pediatric Disease Designation to PYC-001
- Notice of Annual General Meeting/Proxy Form
- US FDA Grants Orphan Drug Designation to PYC Drug Candidate
- Interim Update on Progress in RP11 Repeat Dose Trials
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics